Delivery order for reagents and consumables for govenrment-owned roche benchmark ultra immunostainers in support of NIH/NCI/CCR/clinical immunohistochemistry laboratory of the laboratory of…
Ended Awarded Last action
- Contract number
- 75N91024F00024
- Awardee
-
Roche Diagnostics Corporation UEI JDMDFEZBYH36
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $600,000
Award facts
- Opportunity
-
- 75N91024Q00097 Solicitation number
- Contract value 100% obligated
- $600,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Castleton, IN 46256, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $250,000 | |
| Exercise an Option | $300,000 | |
| Original award | $50,000 |
About this award
The National Cancer Institute (NCI) awarded a delivery order valued at $600,000 to Roche Diagnostics Corporation for reagents and consumables supporting government-owned Roche Benchmark Ultra immunostainers operated by the Clinical Immunohistochemistry Laboratory within the Laboratory of Pathology at the National Institutes of Health's National Cancer Institute Center for Cancer Research. This order represents the second option period under an existing contract vehicle and will be performed in Castleton, Indiana through September 19, 2026. The contract employs firm fixed-price pricing with no set-aside designation, allowing Roche Diagnostics to compete openly in the federal marketplace.
Roche Diagnostics Corporation, a foreign-owned manufacturer of in vitro diagnostic products and laboratory instruments, is a global leader in providing diagnostic solutions to federal healthcare and research agencies. The company maintains an extensive portfolio of federal contracts primarily with the Department of Veterans Affairs and Defense Health Agency, supplying advanced diagnostic technologies including molecular testing equipment, clinical chemistry analyzers, and specialized reagents. This delivery order supports the NCI's critical immunohistochemistry research and diagnostic capabilities, enabling the continuation of pathology services essential to the Institute's cancer research mission.
Description
Delivery order for reagents and consumables for govenrment-owned roche benchmark ultra immunostainers in support of NIH/NCI/CCR/clinical immunohistochemistry laboratory of the laboratory of pathology (LP)
Quick answers
Who was awarded contract 75N91024F00024?
75N91024F00024 was awarded to Roche Diagnostics Corporation by National Cancer Institute (National Institutes of Health) on September 20, 2024.
How much is contract 75N91024F00024 worth?
The government has obligated $600,000 on 75N91024F00024.
Is contract 75N91024F00024 an order under another contract?
Yes. 75N91024F00024 is a delivery order under 75N91019D00038, an indefinite delivery contract.
Was contract 75N91024F00024 competed?
The extent of competition for 75N91024F00024 was not competed under sap.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award